Rituximab desensitization in pediatric acute lymphoblastic leukemia with severe anaphylaxis.

Rosalaura V Villarreal González Cindy Elizabeth De Lira-QuezadaSandra N González-DíazLigia L Carrasco-DíazOscar González-Llano

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

HSR to rituximab may be induced by the activation of mast cells and basophils. Desensitization protocols are developed when there is no alternative drug for the underlying condition.

Keyphrases

acute lymphoblastic leukemia
diffuse large b cell lymphoma
chronic lymphocytic leukemia
hodgkin lymphoma
allogeneic hematopoietic stem cell transplantation
early onset
drug induced
adverse drug
electronic health record